| Prednisolone or pentoxifylline for alcoholic hepatitis MR Thursz, P Richardson, M Allison, A Austin, M Bowers, CP Day, ... New England Journal of Medicine 372 (17), 1619-1628, 2015 | 853 | 2015 |
| The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis M Carbone, SJ Sharp, S Flack, D Paximadas, K Spiess, C Adgey, ... Hepatology 63 (3), 930-950, 2016 | 388 | 2016 |
| Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study E Scorletti, L Bhatia, KG McCormick, GF Clough, K Nash, L Hodson, ... Hepatology 60 (4), 1211-1221, 2014 | 363 | 2014 |
| Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR S Knapp, LJ Yee, AJ Frodsham, BJW Hennig, S Hellier, L Zhang, ... Genes & Immunity 4 (6), 411-419, 2003 | 312 | 2003 |
| Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP–2, with outcome of HCV infection S Hellier, AJ Frodsham, BJW Hennig, P Klenerman, S Knapp, P Ramaley, ... Hepatology 38 (6), 1468-1476, 2003 | 271 | 2003 |
| Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. M Wright, R Grieve, J Roberts, J Main, HC Thomas, ... Health technology assessment (Winchester, England) 10 (21), 1-iii, 2006 | 269 | 2006 |
| Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection S Knapp, BJW Hennig, AJ Frodsham, L Zhang, S Hellier, M Wright, ... Immunogenetics 55, 362-369, 2003 | 245 | 2003 |
| Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection M Wright, R Goldin, S Hellier, S Knapp, A Frodsham, B Hennig, A Hill, ... Gut 52 (8), 1206-1210, 2003 | 201 | 2003 |
| In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels … N Vergis, SR Atkinson, S Knapp, J Maurice, M Allison, A Austin, ... Gastroenterology 152 (5), 1068-1077. e4, 2017 | 194 | 2017 |
| Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease E Scorletti, PR Afolabi, EA Miles, DE Smith, A Almehmadi, A Alshathry, ... Gastroenterology 158 (6), 1597-1610. e7, 2020 | 181 | 2020 |
| Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study M Wright, R Goldin, A Fabre, J Lloyd, H Thomas, C Trepo, P Pradat, ... Gut 52 (4), 574-579, 2003 | 176 | 2003 |
| Cost effectiveness of interferon α or peginterferon α with ribavirin for histologically mild chronic hepatitis C R Grieve, J Roberts, M Wright, M Sweeting, D DeAngelis, W Rosenberg, ... Gut 55 (9), 1332-1338, 2006 | 140 | 2006 |
| Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score M Carbone, A Nardi, S Flack, G Carpino, N Varvaropoulou, C Gavrila, ... The Lancet Gastroenterology & Hepatology 3 (9), 626-634, 2018 | 138 | 2018 |
| Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies QM Anstee, RD Goldin, M Wright, A Martinelli, R Cox, MR Thursz Journal of Thrombosis and Haemostasis 6 (8), 1336-1343, 2008 | 137 | 2008 |
| Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence AJ Frodsham, L Zhang, U Dumpis, NAM Taib, S Best, A Durham, ... Proceedings of the National Academy of Sciences 103 (24), 9148-9153, 2006 | 123 | 2006 |
| An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ... Journal of hepatology 75 (3), 572-581, 2021 | 111 | 2021 |
| Parenchymal extinction: coagulation and hepatic fibrogenesis QM Anstee, M Wright, R Goldin, MR Thursz Clinics in liver disease 13 (1), 117-126, 2009 | 108 | 2009 |
| Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis EH Forrest, SR Atkinson, P Richardson, S Masson, S Ryder, MR Thursz, ... Journal of hepatology 68 (3), 511-518, 2018 | 95 | 2018 |
| Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial E Forrest, J Mellor, L Stanton, M Bowers, P Ryder, A Austin, C Day, ... Trials 14, 1-7, 2013 | 89 | 2013 |
| Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection BJW Hennig, S Hellier, AJ Frodsham, L Zhang, P Klenerman, S Knapp, ... Genes & Immunity 3 (6), 359-367, 2002 | 88 | 2002 |
